Amgen (AMGN) cash: $9.1B
Amgen held $9.1B in cash and cash equivalents on Dec 31, 2025, down 23.8% from $12B a year earlier.
From Amgen's filings with the SEC · Read the filing · AMGN stock page
Amgen cash by year
#71 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $9.1B | -24% |
| Dec 31, 2024 | $12B | +9% |
| Dec 31, 2023 | $10.9B | +43% |
| Dec 31, 2022 | $7.6B | -5% |
| Dec 31, 2021 | $8B | – |
Cash of similar companies
Companies in the same industry as Amgen, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Amgen | $9.1B | Dec 31, 2025 |
| Gilead Sciences | $7.6B | Dec 31, 2025 |
| Biogen | $3B | Dec 31, 2025 |
| Moderna | $2.6B | Dec 31, 2025 |
| Immunovant | $995M | Dec 31, 2025 |
| Qiagen | $839M | Dec 31, 2025 |
| Recursion Pharmaceuticals | $743M | Dec 31, 2025 |
Questions and answers
What is Amgen's cash?
Amgen held $9.1B in cash and cash equivalents on Dec 31, 2025, down 23.8% from $12B a year earlier.
Numbers as reported in Amgen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology